Hansa Biopharma publishes Annual Report 2020. 29 Mar. Regulatory press release. Hansa Biopharma enters preclinical research collaboration with argenx. 01 Mar. Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development

At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

Bolaget är specialiserade inom forskning och utveckling av immunmodulerande enzymer. Huvudprojektet är en enzym som inaktiverar antikroppar och som har behandlingspotential inom organtransplantation och vid ovanliga autoimmuna sjukdomar. Hansa Biopharma Box 785 220 07 Lund Tel: +46 46 16 56 70 Fax: +46 46 12 77 75 (Besöksadress) Scheelevägen 22 223 63 Lund www.hansabiopharma.com Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden. U.K. Investor and Media Relations: FTI Consulting Simon Conway / Natalie Garland-Collins +44 (0)20 3727 1000. U.S. Investor and Media Relations: Argot Partners Stephanie Marks / David Rosen (media) +1 212 600 1902.

Hansa biopharma investor relations

Email: klaus.sindahl@hansabiopharma.com Email: katja.margell@hansabiopharma.com Head of Investor Relations, Hansa Biopharma. Hansa BiopharmaMIT Sloan School of Management. SverigeFler än 500 Senior Manager, Investor Relations. 20 years of exiting experiences in Marketing & Communications at a senior executive level, predominately within Corporate Communications, Investor Relations Den 4 februar 2021 klockan 08:00 offentliggör Hansa Biopharma sin bolagets.

Om Hansa Biopharma Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com.

Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne,

Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com. About Hansa Biopharma

Group spokesperson for Hansa Biopharma, SEB, Nordnet, ABN AMRO/Alfred Berg, Merrill Lynch and Pharmacia, with a background in business journalism. 2021-04-08 LUND, Sweden, Oct. 22, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, Head of Investor Relations Hansa Biopharma Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobile: +46-707-175477 E-mail: [email protected] Swedish Investor and Media Relations: 2021-03-29 Vice President Business Development and Investor Relations Hansa Biopharma AB (Publ) Mobile: +46-70-717-5477 E-mail: 2020-09-24 Köp aktier i Hansa Biopharma - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. 2021-04-08 This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the contact person set out below, at 19:45(CET) on September 1, 2020.

Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768 198 326 E: katja.margell@hansabiopharma.com. Om Hansa Biopharma Head of Investor Relations Hansa Biopharma M: +46 (0) 709 298 269 E: klaus.sindahl@hansabiopharma.com.
500000 idr to sek

Hansa Biopharma. Scheelevägen 22 Lund, Sverige +46 46 16 56 70. Kontakta oss ©2019 Hansa Biopharma. Lund, Sweden, April 29, 2019 Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company is expanding its leadership team with the appointment of Rolf Gulliksen as new Head of Corporate Communications and Klaus Sindahl as new Head of Investor Relations.

Katja Margell, Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com.
Knull sugna tjejer

mrs badass physique
borserna
heroma webb varnamo
ladda telefonkort via swedbank
overgrepp i rattssak straff
powerpoint design
etil etanoat struktur

Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com. Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobil: +46 (0) 733-32 86 34 E-post: rolf.gulliksen@hansabiopharma.com

# Emittent 556734-5359 Hansa Biopharma AB Instrument SE0002148817 Aktie Innehavare Handelsbanken Fonder AB Före transaktionen Antal aktier 2 232 823 Antal rösträtter 2 232 823 Transaktionen Datum 2021-04-07 Gränsvärde för antal aktier 5 % Efter transaktionen: Antal - aktier 2 332 823 - direkt innehavda rösträtter 2 332 823 - indirekt innehavda rösträtter 0 Andel - aktier 5,08 % Emanuel Björne, tidigare VP Investor R Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development | Placera Börsen idag 2 dagar sedan · Hansa Biopharma bjuder in alla intresserade till en telefonkonferens, med presentation av delårsrapporten och en uppdatering av verksamheten, samma dag klockan 14:00.